Pancreatic Cancer Clinical Trials in Cleveland

Showing 81-81 of 81 trials

A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

NCT00179751

Phase I will determine the MDT and evaluate the safety profile of oral lenalidomide days 1-21 and weekly gemcitabine days 1, 8, \& 15 in 28 day cycles Phase II will explore the anti-tumor activity and safety of the combination in subjects with advanced pancreatic carcinoma. Subjects will receive oral lenalidomide days 1-21 and weekly gemcitabine days 1, 8, \& 15 in 28 day cycles until documented disease progression occurs.

Pancreatic Cancer

Celgene Corporation50 participantsStarted Apr 2005

Metairie, Louisiana, United States • St Louis, Missouri, United States • Cleveland, Ohio, United States +3 more locations

PreviousPage 5 of 5

A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

Pancreatic Cancer Trials in Other Cities

Other Conditions in Cleveland